Profile data is unavailable for this security.
About the company
Cellectar Biosciences, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The Company, through phospholipid ether drug conjugate (PDC) delivery platform, is focused on developing PDCs that are designed to specifically target cancer cells. Its PDC platform possesses the potential for the discovery and development of cancer-targeting treatments, and it plans to develop PDCs both independently and through research and development collaborations. Its product pipeline includes iopofosine, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope), preclinical PDC chemotherapeutic programs and multiple partnered PDC assets. Its Iopofosine is evaluated in the completed CLOVER-WaM Phase 2 pivotal study in patients with relapsed/refractory (r/r) Waldenstrom’s macroglobulinemia (WM).
- Revenue in USD (TTM)0.00
- Net income in USD-50.98m
- Incorporated1996
- Employees20.00
- LocationCellectar Biosciences Inc100 Campus DriveFLORHAM PARK 07932United StatesUSA
- Phone+1 (608) 441-8120
- Fax+1 (608) 441-8121
- Websitehttps://www.cellectar.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tiziana Life Sciences Ltd - ADR | 0.00 | -15.40m | 103.08m | 9.00 | -- | 5.23 | -- | -- | -0.1496 | -0.1496 | 0.00 | 0.1914 | 0.00 | -- | -- | 0.00 | -40.89 | -- | -50.40 | -- | -- | -- | -- | -- | -- | -2,083.71 | 0.0183 | -- | -- | -- | 34.25 | -- | -- | -- |
| Maia Biotechnology Inc | 0.00 | -23.72m | 103.73m | 13.00 | -- | -- | -- | -- | -1.57 | -1.57 | 0.00 | -0.2801 | 0.00 | -- | -- | 0.00 | -266.70 | -- | -520.49 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -21.91 | -- | -- | -- |
| Hongchang International Co Ltd | 2.67m | -365.80k | 103.82m | 8.00 | -- | 2.62 | -- | 38.93 | -0.0006 | -0.0006 | 0.0055 | 0.0763 | 0.0993 | -- | 175.86 | -- | -1.36 | -7.98 | -1.42 | -10.94 | 3.03 | 11.47 | -13.72 | -64.88 | 5.86 | -- | 0.2263 | -- | 3,289.22 | -- | -42.63 | -- | -- | -- |
| Vistagen Therapeutics Inc | 1.04m | -32.07m | 104.32m | 37.00 | -- | 0.8462 | -- | 100.08 | -3.56 | -3.56 | 0.0775 | 4.56 | 0.013 | -- | -- | 31,584.85 | -39.89 | -77.80 | -42.10 | -85.00 | -- | -- | -3,076.62 | -8,640.25 | -- | -- | 0.00006 | -- | -120.50 | -- | -21.64 | -- | 165.73 | -- |
| Clearside Biomedical Inc | 8.45m | -34.97m | 104.62m | 30.00 | -- | -- | -- | 12.38 | -0.543 | -0.543 | 0.1321 | -0.2919 | 0.1993 | -- | -- | 281,733.30 | -82.44 | -63.57 | -94.63 | -81.77 | 93.08 | -- | -413.72 | -231.80 | -- | -- | -- | -- | 519.89 | 207.34 | 1.40 | -- | 82.41 | -- |
| Eledon Pharmaceuticals Inc | 0.00 | -39.85m | 105.89m | 20.00 | -- | 0.912 | -- | -- | -1.41 | -1.41 | 0.00 | 3.02 | 0.00 | -- | -- | 0.00 | -48.86 | -38.44 | -51.95 | -39.80 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 54.16 | -- | -- | -- |
| Omega Therapeutics Inc | 4.94m | -92.28m | 109.21m | 93.00 | -- | 2.64 | -- | 22.11 | -1.67 | -1.67 | 0.0896 | 0.7498 | 0.029 | -- | 6.08 | 53,107.53 | -54.28 | -- | -62.10 | -- | -- | -- | -1,868.35 | -- | -- | -- | 0.302 | -- | 49.25 | -- | 5.13 | -- | -- | -- |
| PDS Biotechnology Corp | 0.00 | -43.89m | 109.30m | 25.00 | -- | 2.94 | -- | -- | -1.37 | -1.37 | 0.00 | 1.01 | 0.00 | -- | -- | 0.00 | -63.85 | -51.63 | -74.22 | -59.00 | -- | -- | -- | -- | -- | -27.82 | 0.3933 | -- | -- | -- | -5.11 | -- | -- | -- |
| DiaMedica Therapeutics Inc | 0.00 | -19.26m | 110.10m | 18.00 | -- | 2.38 | -- | -- | -0.5532 | -0.5532 | 0.00 | 1.22 | 0.00 | -- | -- | 0.00 | -48.47 | -45.38 | -52.02 | -48.24 | -- | -- | -- | -- | -- | -- | 0.00006 | -- | -- | -- | -41.72 | -- | -13.65 | -- |
| Allakos Inc | 0.00 | -214.44m | 110.68m | 131.00 | -- | 1.05 | -- | -- | -2.45 | -2.45 | 0.00 | 1.18 | 0.00 | -- | -- | 0.00 | -81.27 | -42.71 | -92.78 | -45.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 41.96 | -- | -38.89 | -- |
| Cellectar Biosciences Inc | 0.00 | -50.98m | 110.77m | 20.00 | -- | 11.28 | -- | -- | -3.17 | -3.17 | 0.00 | 0.789 | 0.00 | -- | -- | 0.00 | -176.58 | -83.69 | -295.36 | -99.80 | -- | -- | -- | -- | -- | -4.81 | 0.00 | -- | -- | -- | -32.80 | -- | 17.55 | -- |
| Coya Therapeutics Inc | 6.13m | -10.30m | 111.39m | 8.00 | -- | 3.44 | -- | 18.17 | -0.8899 | -0.8899 | 0.5401 | 2.22 | 0.2236 | -- | -- | 766,131.30 | -37.59 | -- | -41.86 | -- | -- | -- | -168.11 | -- | -- | -- | 0.00 | -- | -- | -- | 34.77 | -- | -- | -- |
| Immunic Inc | 0.00 | -97.92m | 111.70m | 77.00 | -- | 1.34 | -- | -- | -1.84 | -1.84 | 0.00 | 0.9278 | 0.00 | -- | -- | 0.00 | -91.94 | -72.09 | -110.91 | -80.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 22.25 | -- | -10.97 | -- |
| Karyopharm Therapeutics Inc | 140.46m | -146.34m | 114.07m | 325.00 | -- | -- | -- | 0.8121 | -1.28 | -1.28 | 1.22 | -1.45 | 0.5298 | 1.67 | 4.24 | 432,187.70 | -55.19 | -53.02 | -72.56 | -65.85 | 96.08 | 97.18 | -104.18 | -125.15 | 2.99 | -9.66 | 2.25 | -- | -7.03 | 36.93 | 13.43 | -- | -- | -- |
| Amylyx Pharmaceuticals Inc | 398.00m | -71.10m | 116.97m | 384.00 | -- | 0.3604 | -- | 0.2939 | -1.07 | -1.07 | 5.74 | 4.77 | 0.9644 | 6.74 | 21.00 | 1,036,461.00 | -17.23 | -- | -20.84 | -- | 88.93 | -- | -17.86 | -- | 4.48 | -- | 0.00 | -- | 1,612.94 | -- | 124.84 | -- | -- | -- |
| Sangamo Therapeutics Inc | 18.76m | -328.05m | 117.12m | 405.00 | -- | 2.03 | -- | 6.24 | -1.86 | -1.86 | 0.1057 | 0.2784 | 0.0659 | -- | 4.86 | 46,311.11 | -115.20 | -26.09 | -139.17 | -31.04 | -- | -- | -1,749.06 | -136.53 | -- | -- | 0.00 | -- | 58.34 | 15.85 | -34.09 | -- | -13.25 | -- |
Data as of May 31 2024. Currency figures normalised to Cellectar Biosciences Inc's reporting currency: US Dollar USD
22.93%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| AIGH Capital Management LLCas of 31 Mar 2024 | 2.80m | 7.82% |
| Nantahala Capital Management LLCas of 31 Mar 2024 | 1.87m | 5.23% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 1.19m | 3.32% |
| Adar1 Capital Management LLCas of 31 Mar 2024 | 642.54k | 1.79% |
| Rosalind Advisors, Inc.as of 31 Mar 2024 | 621.48k | 1.73% |
| Barclays Capital, Inc.as of 31 Mar 2024 | 338.20k | 0.94% |
| Geode Capital Management LLCas of 31 Mar 2024 | 316.08k | 0.88% |
| Hudson Bay Capital Management LPas of 31 Mar 2024 | 150.00k | 0.42% |
| Acuta Capital Partners LLCas of 31 Mar 2024 | 143.50k | 0.40% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 142.38k | 0.40% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
